A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
Boehringer Ingelheim · Healthy · Obesity
Phase 1
Recruiting
80
2026-07
Evidence dashboardStudies since 2017Updated Jul 31, 2026
SurvodutideClinical Trials.
A source-linked view of every Survodutide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 31
- Recruiting
- 3
- Completed
- 24
- Terminated
- 0
- Results posted
- 3
- Average enrollment
- 433
- Countries
- 46
- Highest phase
- Phase 3
Largest indexed study
5,531 participants · NCT06077864 →Developer / research origin
Boehringer Ingelheim / Zealand Pharma
Evidence summary
Activity is not efficacy.
Survodutide appears in 31 indexed studies: 3 recruiting, 24 completed and 3 with registry results posted. The highest registered development stage in this snapshot is Phase 3. These counts measure registry activity; they do not establish that Survodutide is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
Boehringer Ingelheim · Obesity
Phase 1
Active, not recruiting
29
2026-07
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Boehringer Ingelheim · Metabolic Dysfunction Associated Steatohepatitis (MASH) · Liver Fibrosis
Phase 3
Recruiting
1,800
2026-07
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Boehringer Ingelheim · Metabolic Dysfunction Associated Steatohepatitis
Phase 3
Recruiting
1,590
2026-07
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
Boehringer Ingelheim · Obesity
Phase 1
Active, not recruiting
64
2026-05
A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
Boehringer Ingelheim · Healthy
Phase 1
Active, not recruiting
100
2026-03
Showing 6 of 7 studies
NCT IDStudyPhase / statusEnrollmentUpdated
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
Boehringer Ingelheim · Obesity
Phase 3
Completed
5,531
2026-07
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
Boehringer Ingelheim · Obesity · Diabetes Mellitus, Type 2
Phase 3
Completed
755
2026-06
A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector
Boehringer Ingelheim · Healthy · Obesity
Phase 1
Completed
56
2026-06
A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease
Boehringer Ingelheim · Obesity
Phase 3
Completed
274
2026-04
A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight
Boehringer Ingelheim · Obesity · Overweight
Phase 3
Completed
307
2026-04
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
Boehringer Ingelheim · Obesity · Non-Alcoholic SteatoHepatitis (NASH)
Phase 3
Completed
218
2026-04
Showing 6 of 24 studies
No studies in this snapshot.
Full study index
Search Survodutide trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
31 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 39453356 ↗Kosiborod MN, Platz E, Wharton S, le Roux CW, Brueckmann M, Ajaz Hussain S, Unseld A, Startseva E, Kaplan LM; SYNCHRONIZE-CVOT Trial Committees and Investigators. Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial. JACC Heart Fail. 2024 Dec;12(12):2101-2109. doi: 10.1016/j.jchf.2024.09.004. Epub 2024 Oct 23.Linked from NCT06077864PMID 41216778 ↗Wharton S, le Roux CW, Bozkurt B, Platz E, Bleckert G, Ajaz Hussain S, Brueckmann M, Startseva E, Kloer IM, Kaplan LM. Baseline characteristics in the SYNCHRONIZE-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes. Diabetes Obes Metab. 2026 Feb;28(2):1490-1498. doi: 10.1111/dom.70263. Epub 2025 Nov 11.Linked from NCT06066528PMID 42219222 ↗Yokote K, Yamauchi T, Fukushima Y, Takatsuka Y, Kato M, Yan S, Inoue T, Borowska L, Brueckmann M, Ogawa W; SYNCHRONIZE-JP Trial Investigators. Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial. Diabetes Obes Metab. 2026 May 31. doi: 10.1111/dom.70862. Online ahead of print.Linked from NCT06176365PMID 39967239 ↗Younossi ZM, Razavi H, Sherman M, Allen AM, Anstee QM, Cusi K, Friedman SL, Lawitz E, Lazarus JV, Schuppan D, Romero-Gomez M, Schattenberg JM, Vos MB, Wong VW, Ratziu V, Hompesch M, Sanyal AJ, Loomba R. Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective. Aliment Pharmacol Ther. 2025 May;61(9):1467-1478. doi: 10.1111/apt.70020. Epub 2025 Feb 18.Linked from NCT06309992PMID 42253238 ↗le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A, Bozkurt B, Ard JD, Bays HE, Bogdanski P, Ekinci EI, Jastreboff AM, Ji L, Ogawa W, Pedersen SD, Pietilainen KH, Sattar N, Seufert J, Stenlof K, van Beek AP, Vangoitsenhoven R, Brueckmann M, Younes R, Kaplan LM; SYNCHRONIZE-1 Investigators. Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. 2026 Jun 7. doi: 10.1056/NEJMoa2600751. Online ahead of print.Linked from NCT06066515PMID 41187967 ↗le Roux CW, Wharton S, Bozkurt B, Platz E, Bleckert G, Ajaz Hussain S, Brueckmann M, Startseva E, Kloer IM, Kaplan LM. Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE-1). Diabetes Obes Metab. 2026 Jan;28(1):337-346. doi: 10.1111/dom.70196. Epub 2025 Nov 4.Linked from NCT06066515PMID 38847460 ↗Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, Anstee QM, Hussain SA, Newsome PN, Ratziu V, Hosseini-Tabatabaei A, Schattenberg JM, Noureddin M, Alkhouri N, Younes R; 1404-0043 Trial Investigators. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024 Jul 25;391(4):311-319. doi: 10.1056/NEJMoa2401755. Epub 2024 Jun 7.Linked from NCT04771273PMID 38857788 ↗Lawitz EJ, Fraessdorf M, Neff GW, Schattenberg JM, Noureddin M, Alkhouri N, Schmid B, Andrews CP, Takacs I, Hussain SA, Fenske WK, Gane EJ, Hosseini-Tabatabaei A, Sanyal AJ, Mazo DF, Younes R; NCT05296733 Investigators. Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. J Hepatol. 2024 Nov;81(5):837-846. doi: 10.1016/j.jhep.2024.06.003. Epub 2024 Jun 8.Linked from NCT05296733
Related pages
Keep researching Survodutide.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.